Guided Therapeutics (GTHP) Depreciation and Depletion (2014 - 2025)

Guided Therapeutics has disclosed Depreciation and Depletion across 6 years of filings, most recently posting $3000.0 for Q4 2025.

• Depreciation and Depletion for Q4 2025 came in at $3000.0, up 50.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $10000.0 (up 11.11% YoY), and the FY2025 annual result was $10000.0, up 11.11% from the prior year.
• Depreciation and Depletion came in at $3000.0 for Q4 2025 at Guided Therapeutics, up from $2000.0 in the prior quarter.
• In the past five years, Depreciation and Depletion ranged from a high of $2.3 million in Q3 2023 to a low of $1000.0 in Q3 2022.
• The 4-year median for Depreciation and Depletion is $2000.0 (2023), against an average of $167571.4.
• Across the five-year window, Depreciation and Depletion soared 231500.0% in 2023 and sank 99.91% in 2024, its largest moves.
• Guided Therapeutics' Depreciation and Depletion stood at $3000.0 in 2022, then plunged by 33.33% to $2000.0 in 2023, then changed by 0.0% to $2000.0 in 2024, then surged by 50.0% to $3000.0 in 2025.
• The last three Depreciation and Depletion figures came in at $3000.0 (Q4 2025), $2000.0 (Q3 2025), and $3000.0 (Q2 2025), per Business Quant data.